These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8666216)

  • 41. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation.
    Keck PE; McElroy SL
    J Clin Psychiatry; 1992 Apr; 53(4):127-9. PubMed ID: 1564047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of fluoxetine in elderly men and women.
    Ferguson JM; Hill H
    Gerontology; 2006; 52(1):45-50. PubMed ID: 16439824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delirium during fluoxetine treatment. A case report.
    Leinonen E; Koponen H; Lepola U
    Ann Clin Psychiatry; 1993 Dec; 5(4):255-7. PubMed ID: 8312983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.
    Beasley CM; Bosomworth JC; Wernicke JF
    Psychopharmacol Bull; 1990; 26(1):18-24. PubMed ID: 2196623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"?
    Cain JW
    J Clin Psychiatry; 1992 Aug; 53(8):272-7. PubMed ID: 1500403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting response to fluoxetine in geriatric patients with major depression.
    Koran LM; Hamilton SH; Hertzman M; Meyers BS; Halaris AE; Tollefson GD; Downs JM; Folks DG; Jeste DV; Lazarus LW
    J Clin Psychopharmacol; 1995 Dec; 15(6):421-7. PubMed ID: 8748431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions.
    Hawley CJ; Roberts AG; Baldwin DS
    Int Clin Psychopharmacol; 1994; 9(1):31-3. PubMed ID: 8195580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.
    Sonawalla SB; Papakostas GI; Petersen TJ; Yeung AS; Smith MM; Sickinger AH; Gordon J; Israel JA; Tedlow JR; Lamon-Fava S; Fava M
    Psychosomatics; 2002; 43(4):310-6. PubMed ID: 12189257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluoxetine and desipramine in major depressive disorder.
    Bowden CL; Schatzberg AF; Rosenbaum A; Contreras SA; Samson JA; Dessain E; Sayler M
    J Clin Psychopharmacol; 1993 Oct; 13(5):305-11. PubMed ID: 8227488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Once-weekly fluoxetine.
    Wagstaff AJ; Goa KL
    Drugs; 2001; 61(15):2221-8; discussion 2229-30. PubMed ID: 11772132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of fluoxetine on anxiety and depression symptoms in cancer patients.
    Razavi D; Allilaire JF; Smith M; Salimpour A; Verra M; Desclaux B; Saltel P; Piollet I; Gauvain-Piquard A; Trichard C; Cordier B; Fresco R; Guillibert E; Sechter D; Orth JP; Bouhassira M; Mesters P; Blin P
    Acta Psychiatr Scand; 1996 Sep; 94(3):205-10. PubMed ID: 8891089
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluoxetine and suicidal ideation in minor depression.
    Stone MB; Hammad TA
    J Psychiatr Res; 2014 Jan; 48(1):131-2. PubMed ID: 24099987
    [No Abstract]   [Full Text] [Related]  

  • 54. Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments.
    Van Hunsel F; Wauters A; Vandoolaeghe E; Neels H; Demedts P; Maes M
    Psychiatry Res; 1996 Dec; 65(3):159-69. PubMed ID: 9029664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depressive retardation and treatment with fluoxetine: assessment of the motor component.
    Sabbe B; van Hoof J; Hulstijn W; Zitman F
    J Affect Disord; 1997 Mar; 43(1):53-61. PubMed ID: 9127830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Moclobemide and fluoxetine in treatment of seasonal affective disorder.
    Partonen T; Lönnqvist J
    J Affect Disord; 1996 Nov; 41(2):93-9. PubMed ID: 8961036
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse effects of switching from fluoxetine to desipramine.
    Van Ameringen M; Mancini C
    Can J Psychiatry; 1992 May; 37(4):278. PubMed ID: 1611591
    [No Abstract]   [Full Text] [Related]  

  • 58. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.
    Heiligenstein JH; Hoog SL; Wagner KD; Findling RL; Galil N; Kaplan S; Busner J; Nilsson ME; Brown EB; Jacobson JG
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):207-17. PubMed ID: 16553541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.
    Joyce PR; Mulder RT; Luty SE; McKenzie JM; Miller AL; Rogers GR; Kennedy MA
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):339-46. PubMed ID: 14604448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.